Home/ Stocks/ MAIA

MAIA Biotechnology, Inc.

MAIA XASE

$1.44 -0.05 (-3.36%) ▼ 15-min delayed

Open

$1.49

High

$1.50

Low

$1.44

Volume

262.4K

Market Cap

$87.40M

About MAIA Biotechnology, Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 13 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-8,903,189	$-0.27
Q2 2025	$0	$-5,346,963	$-0.18
Q1 2025	$0	$-4,517,259	$-0.16
FY 2024	$0	$-23,254,656	$-1.05

Related Market News

No specific coverage for MAIA yet. Check out our latest market news or earnings calendar.

Get MAIA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on MAIA Biotechnology, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.